Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on YOWIE GROUP LTD. We currently have 6 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
YOWIE GROUP LTD
YOWIE GROUP LTD
Steady course through choppy waters
24 Jan 17
Success for a start-up is rarely a straight line. Production implementation difficulties affected Yowie’s ability to fulfil orders in its December quarter. However, management is sticking to its long-range plans to build on its success in the US by pushing to expand the brand to two to three markets outside the US in FY17. While the expansion timetable is in our view more aggressive than that of similar start-up companies, we believe the investment spending and expansion tactics are quite conservative. Our model now includes our estimates for sales outside the US (OUS); however, it includes more modest revenue and profitability expectations for FY17-19, but we maintain our confidence in the company’s long-term growth and profitability prospects.
Roll-out accomplished - moving to the next phase
12 Dec 16
Yowie is making sound progress against its near-term strategy. At initiation a year ago, the company was very much a start-up story despite its historical success in the 1990s. To this point, management has demonstrated its ability to deliver on its short-term retail goals while anticipating and investing in future opportunities for growth through both in-licensing brands to expand sales, and early plans to leverage the Yowie brand into publishing, entertainment and other products.
04 May 16
An investor day at Yowie’s new manufacturing facility on 25 April revealed a smooth relocation and the successful production of its first in-licensed product – Angry Bird character Yowies – to coincide with the upcoming Angry Birds movie in mid-May. Retail revenues rose another 29% on a sequential basis in the March quarter, to an estimated US$8m as the company filled reorders from existing customers and new customers including Walgreens. Volumes appear in line with our estimates so we are maintaining our top-line expectations for now. We will revisit our forecasts after the FY16 results in September when more information is available on the reduction of patent royalty fees resulting from the new contract manufacturer, as well as any additional cost savings.
26 Feb 16
Yowie Group’s retail revenues rose 29% on a sequential basis in the December quarter to an estimated US$6.2m as the company completed its roll-out to 4,300 Walmart stores in the US. December quarter numbers include both retail and stock-building sales, so we are maintaining our topline expectations for now. However, based on the company’s recent move to a new contract manufacturer and the resulting discontinuation of patent royalty fees, we believe there may be upside to our estimates.
Walmart rollout leads to record sales
06 Nov 15
Yowie Group’s retail revenues doubled on a sequential basis in the September quarter to an estimated US$4.8m as the company expands its rollout from 1,500 to 4,300 Walmart stores in the US. With the Walmart rollout nearly complete, inventory-related working capital needs are declining, improving operating cash flow trends. Based on these early results, we believe there may be upside to our fiscal 2016 base case outlook. However, we are maintaining our estimates for now as the September quarter numbers reflect both retail and stock-building sales.
Confectionery with a conscience
21 Sep 15
Yowie Group has a clear brand vision rooted in the natural world and an exciting near-term strategy, based on legally protected US barriers to entry. We forecast rapid sales growth as the company executes on the opportunity led by its product rollout to over 4,300 Walmart stores in the US. Although that growth is being recognized in the share price, upside remains, and we suggest neither international expansion nor significant wider product and licensing activities are yet reflected by the market.
Eyeing Up Opportunity
24 Mar 17
Produce Investment’s (PIL LN, BUY, T/P 210p) interim profits were well beneath inferred market expectations as delays in the recovery of ex-farm potato prices coincided with unusual costs associated with the company’s implementation of a new ERP system. Interim EBIT fell to £0.2m from £3.4m last year.
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
N+1 Singer - Morning Song 28-03-2017
28 Mar 17
A G Barr (BAG LN) Share buybacks the main news around FY17 finals | Churchill China (CHH LN) An excellent set of 2016 results and more upgrades | Ergomed (ERGO LN) FY results show strong Services growth; Phase III Zoptrex® data ahead | Instem (INS LN) Investment to accelerate growth trajectory | Severfield (SFR LN) Strong H2 drives upgrades; CEO temporarily steps down due to ill health | Summit Therapeutics (SUMM LN) Strengthening the data package: planned extension of PhaseOut DMD | T. Clarke (CTO LN) Strong conclusion to FY16, record order book
Hardman & Co Monthly: March 2017
01 Mar 17
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.